Statement: More patients in cohort 1 of the primary trial experienced death progressive disease  than in cohort 2.
Primary_evidence: Adverse Events 1:   Total: 6/15 (40.00%)   diarrhea and dehydration * 0/15 (0.00%)   Severe Dehydration * 1/15 (6.67%)   hypokalemia * 1/15 (6.67%)   pain, swelling, mastectomy site cellulitis * 0/15 (0.00%)   death progressive disease * 0/15 (0.00%)   divetricular abscess * 0/15 (0.00%)   fever * 1/15 (6.67%)   febrile neutropenia * 3/15 (20.00%)   Neutropenia * 0/15 (0.00%) Adverse Events 2:   Total: 4/14 (28.57%)   diarrhea and dehydration * 0/14 (0.00%)   Severe Dehydration * 0/14 (0.00%)   hypokalemia * 0/14 (0.00%)   pain, swelling, mastectomy site cellulitis * 0/14 (0.00%)   death progressive disease * 1/14 (7.14%)   divetricular abscess * 0/14 (0.00%)   fever * 0/14 (0.00%)   febrile neutropenia * 2/14 (14.29%)   Neutropenia * 0/14 (0.00%)